NYU Technology Opportunities & Ventures

What NYU Technology Opportunities & Ventures does

Technology Opportunities & Ventures (TOV) is the centralized technology commercialization and transfer office of New York University and NYU Langone Health, headquartered in New York City with a secondary event presence in Long Island City and a dedicated Director for the NYU Abu Dhabi campus. The organization translates the University's $1.5 billion research base into commercial outcomes, currently overseeing 1,600+ U.S. patents, 240+ executed license agreements, 200+ startups, and 50+ products brought to market since 1980. It operates a portfolio of interconnected programs rather than a single product: Therapeutics Alliances, a drug-discovery accelerator managing 20+ active projects with translational awards up to $300K; the NYU Langone Health Venture Fund for seed-stage biomedical investments; the MedTech Venture Prototyping Fund (up to $75K) and TAC Awards (up to $75K) for early-stage development; the Biomedical Entrepreneurship Program and NYU Entrepreneurial Institute for innovator education; the Mentors in Residence Program for founder support; and technology platforms including the Innovation Disclosure Portal (Kerberos-authenticated) and the Technology Licensing Portal (license.tov.med.nyu.edu). The COMAI consortium extends the offering into operational medical AI industry engagement.

The business model is a hybrid of licensing royalties, equity holdings in spinout startups, and sponsored research agreements with industry partners. Revenue mechanics are case-by-case negotiation rather than standardized pricing. Distribution is primarily B2B through the licensing portal, direct business development outreach, and event-driven engagement (IXI Investor & Innovator Exchange, Industry Days, Innovators' Dinner, SciCafé). Customers are dual-sided: internal NYU/NYU Langone faculty innovators (the primary persona), and external pharmaceutical, biotechnology, medical device, and digital health enterprises seeking access to early-stage technologies and collaborative research. TOV does not generate independent revenue as a standalone P&L; its operations are funded through NYU/NYU Langone's research budgets, grant programs, and institutional partnerships including the $130 million, 10-year Deerfield Management commitment through Amethyst Innovations. The organization is led by Vice President Marc Sedam and a team of 16 including directors of life sciences, physical sciences, IP, contracts, finance, Therapeutics Alliances, and AI program roles.

Name

NYU Technology Opportunities & Ventures

Legal name

Technology Opportunities & Ventures

Website

https://tov.med.nyu.edu

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

NYU Technology Opportunities & Ventures is the technology commercialization unit of NYU and NYU Langone Health, translating the university's $1.5 billion research base into licensed technologies, startup spinouts, and pharma partnerships. It serves NYU faculty innovators and pharmaceutical/biotech industry partners through integrated programs spanning disclosure, funding, licensing, and venture formation.

Ownership category

akta.pro rank

Product category

Technology Transfer and Commercialization Services

NAICS

Scientific Research and Development Services (5417), Professional, Scientific, and Technical Services (54)

SIC

Patent Owners & Lessors (6794), Services-Management Consulting Services (8742)

akta.pro primary industry

IP Licensing, Transactions & Technology Transfer (BPAHAMAF)

akta.pro secondary industries

Technology Transfer & Innovation-Driven Research Universities (High Commercialization) (EDAHABAH), Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Technology transfer services
• University technology licensing
• Biomedical research commercialization
• Academic startup incubation
• Intellectual property management

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. Technology Licensing Royalties: TOV generates revenue through licensing agreements with industry partners for technologies developed at NYU. These include license fees, milestone payments, and ongoing royalties from commercialized products.
2. Equity Holdings in Startups: NYU Langone Health, through TOV, holds equity positions in startup companies spun out from NYU research, including Aethon Therapeutics and Ajax Therapeutics.
3. Sponsored Research Agreements: TOV facilitates industry-sponsored research collaborations with NYU faculty, generating funding through research agreements with pharmaceutical and biotech companies.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

NYU Technology Opportunities & Ventures is the technology commercialization unit of New York University and NYU Langone Health, providing end-to-end technology transfer services including innovation disclosure processing, patent protection, market assessment, licensing negotiation, startup formation, and portfolio management. TOV earns revenue through technology licensing royalties, sponsored research agreements, and equity holdings in spinout companies, drawing on NYU's $1.5 billion research base and a portfolio of 1,600+ U.S. patents. Its offerings include the Therapeutics Alliances drug accelerator, the NYU Langone Health Venture Fund, intramural proof-of-concept funding programs (TAC Awards, MedTech Venture Prototyping Fund), the Biomedical Entrepreneurship Program, and online licensing and disclosure portals.

Product overview

NYU Technology Opportunities & Ventures (TOV) is the technology commercialization unit of NYU and NYU Langone Health, operating as a portfolio of interconnected programs rather than a single product. The core offerings include: Therapeutics Alliances, a drug discovery accelerator that manages 20+ active projects; the NYU Langone Health Venture Fund for seed-stage biomedical investments; MedTech Venture Prototyping Fund and TAC Awards for early-stage funding; the Biomedical Entrepreneurship Program and NYU Entrepreneurial Institute for startup education and incubation; and technology licensing platforms (Search Technologies portal and Innovation Disclosure Portal). These programs work together to move research discoveries from laboratory to market, with TOV having facilitated over 50 products on the market, 1,600+ U.S. patents, and 240+ license agreements.

Differentiator

Problem solved

Functional benefit

Brands

• Therapeutics Alliances: A unique and comprehensive drug accelerator that identifies select NYU projects to facilitate dealmaking with investors and biopharmaceutical companies.
• NYU Langone Health Venture Fund

Products and services

• Therapeutics Alliances A drug accelerator program that identifies select NYU projects to facilitate dealmaking with investors and biopharmaceutical companies, providing resources for target discovery, validation, assay development, hit finding, and hit-to-lead optimization. Manages 20+ active drug discovery projects as a virtual biotech with experienced project managers, external pharma consultants, and a CRO network.
• NYU Langone Health Venture Fund Strategic seed-stage investment fund for biomedical startups leveraging NYU technologies, providing capital, ecosystem support, and access to medical expert networks.
• MedTech Venture Prototyping Fund Intramural funding program supporting advancement of medical device and digital health technologies through prototype development and evaluation. Offers up to $75,000 for advanced-stage projects and up to $25,000 for early concept stage.
• Technology Acceleration & Commercialization (TAC) Awards Funding awards supporting NYU innovations with high commercialization potential through proof-of-concept studies and prototype development. Awards up to $75,000 for up to one year.
• Therapeutics Alliances RFP - Translational Awards Translational grants supporting preclinical research in drug target selection, validation, and hit-to-lead screening. Awards range from $75,000 to $300,000 depending on project type.
• Biomedical Entrepreneurship Program Year-long educational program teaching how to commercialize biomedical discoveries. Includes the Introduction to Biomedical Entrepreneurship course covering drug, device, and digital health commercialization.
• NYU Entrepreneurial Institute University-wide initiative accelerating technology commercialization and startup launches. Provides training, educational programming, events, and funding resources through the Leslie Entrepreneurs Lab.
• Mentors in Residence Program Startup support program providing mentorship to founders working to commercialize NYU innovations.
• Technology Licensing Portal Online platform for browsing and licensing NYU technologies. Provides a searchable database of available technologies across multiple categories including therapeutics, medical devices, diagnostics, engineering, and creative works.
• Innovation Disclosure Portal Online submission system enabling NYU researchers to formally disclose innovations using Kerberos ID authentication. The first formal step for obtaining IP protection and commercialization support.
• Consortium for Operational Medical AI (COMAI) Industry consortium focused on advancing operational medical AI technologies and applications, providing a structured engagement pathway for AI and healthcare companies.
• Sponsored Research Partnerships Industry-sponsored research collaborations connecting NYU faculty with pharmaceutical, biotech, and other industry partners for collaborative development of new technologies.

Quantifiable outcome

• 428 new disclosures, 109 executed licenses, 20 newly launched startups in FY2025 alone
• +2 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature2 records

Partnerships

Five partnerships are on record, tiered core.

• AstraZenecacoreStrategic or Co-development Partner · 1 June 2026NYU Langone hosted AstraZeneca for Oncology Industry Day to deepen collaboration across clinical research, translational science, and therapeutic development. Organized by TOV with Perlmutter Cancer Center's Clinical Trials Office. Focus areas: lung cancer, GI cancers, breast cancer, hematology, and cell therapy.
• OpenTronscoreStrategic or Co-development PartnerPartnership with Dr. Jef Boeke's lab created the Pandemic Response Lab for COVID-19 testing and genomic sequencing. Led to OpenTrons' $200M Series C at $1.85B valuation (NYC's first biotech unicorn) and acquisition of NYU startup Neochromosome.
• Biolabs@NYULangonecoreStrategic or Co-development PartnerCo-host of the 2026 Investor & Innovator Exchange (IXI) event, providing networking opportunities between startup founders, investors, and industry experts in life sciences.
• Weizmann Institute of Science / Yeda ResearchcoreStrategic or Co-development PartnerCo-founded UltraSight with NYU and Weizmann Institute, with Yeda as Weizmann's technology transfer company. TOV provided seed funding, filed patents, and negotiated the startup license.
• NYU Tandon School of Engineering / mLabcoreTechnology or IntegrationMobile Defender spun out from NYU Tandon's mLab led by Professor Danny Huang. The lab focuses on building tools to address real-world security and privacy threats in healthcare and consumer technologies.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Columbia Technology Ventures: Columbia University's tech transfer office, operating in the same New York metro and serving the same faculty and industry base; competes directly for talent, licensing deals, and startup spinouts.
• Johns Hopkins Technology Ventures: Johns Hopkins Technology Ventures is a peer biomedical-heavy TTO with overlapping licensing, startup support, and industry partnership programs.
• Penn Center for Innovation: University of Pennsylvania's tech transfer and ventures operation overlaps heavily with NYU in biomedical and health-tech commercialization at a top-tier research university.
• Harvard Office of Technology Development (OTD): Harvard OTD is a leading East Coast peer TTO with a similar broad portfolio across life sciences, physical sciences, and digital health, and competes for biopharma licensing deals.
• Yale Office of Cooperative Research (OCR): Yale's tech transfer and industry collaboration office is a comparable East Coast biomedical-heavy TTO with shared licensing and startup formation economics.
• UCSF Innovation Ventures: UCSF's tech transfer operation is a peer biomedical TTO competing for biopharma licensing deals and equity investments in academic spinouts.
• Stanford Office of Technology Licensing (OTL): Stanford OTL is the historical benchmark for university technology transfer, operating a similar licensing and equity-stake model across therapeutics, devices, and software inventions.
• MIT Technology Licensing Office: MIT's tech transfer office is a top-five U.S. peer with a comparable pipeline model, deeply integrated into life sciences, physical sciences, and engineering commercialization.
• Duke Office for Translation and Commercialization: Duke's tech transfer office operates a similar licensing + venture fund model in life sciences and is a direct peer for biomedical startup formation.
• Georgia Tech Research Corporation (GTRC): GTRC is the tech transfer arm of a major research university with a similar broad portfolio across engineering and physical sciences; referenced in TOV's own staff backgrounds as a peer model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/NYUTOV
• LinkedInlinkedin.com/company/nyu-technology-opportunities-and-ventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NYU Technology Opportunities & Ventures